No profile data available.
Lipocine Inc. (LPCN) is a healthcare company in the additional hormone and metabolic drugs industry, based in Salt Lake City, United States, with about 14 full-time employees.
It reported revenue of $1.98 million for fiscal year 2025, down 82.3% from fiscal year 2024, and net income of -$9.63 million. Its market capitalization was $14.18 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Lipocine reported $1.98 million in revenue for fiscal year 2025, down 82.3% from $11.20 million in fiscal year 2024.
$14.18 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional hormone and metabolic drugs) include Spruce Biosciences, Inc. (SPRB), International Isotopes Inc. (INIS), RADNOSTIX INC (INIS).